FDA UDI, device by device.
FDA's Unique Device Identification rule requires most medical devices sold in the US to carry a UDI on the label and package, in plain text and machine-readable form, with key data submitted to the GUDID database.
FDA's Unique Device Identification rule requires most medical devices sold in the US to carry a UDI on the label and package, in plain text and in a machine-readable form, and to have key data submitted to the Global Unique Device Identification Database (GUDID). The rule phased in by risk class from 2014 to 2018. FDA's grace policies for most class II and class III devices have ended, so those devices should carry a UDI now unless an alternative or exception applies.
FDA UDI for medical devices, in three facts.
21 CFR Part 801 and Part 830 · class III from 24 Sep 2014 · class II from 24 Sep 2016 · class I from 24 Sep 2018 · data to GUDID · direct mark for reusable devices.
FDA's UDI rule phased in by risk: class III devices from 24 September 2014, implantable and life-supporting devices from 24 September 2015, class II from 24 September 2016 and class I from 24 September 2018.
Source: FDA, UDI system overview (compliance dates)FDA's compliance policies for non-sterile class III, class II and implantable, life-supporting or life-sustaining devices are no longer in effect: these devices should bear a UDI unless an FDA-granted alternative or exception applies.
Source: FDA, Compliance dates for UDI requirementsClass I devices exempt from current good manufacturing practice are excepted from FDA's UDI requirements under 21 CFR 801.30(a)(2).
Source: FDA, Compliance dates for UDI requirements
One identifier, on the device and in the database.
A UDI on the label and package
The UDI has a device identifier, fixed for a model, and production identifiers such as lot, serial number or expiry date. It appears in plain text and in an AIDC form such as a barcode.
Data in GUDID
The labeler submits each device identifier's key data to FDA's GUDID database, which the public can search.
Direct marking for reusable devices
Devices meant to be used more than once and reprocessed between uses carry the UDI on the device itself, so it survives once the label is gone.
Who is excepted
Class I devices exempt from current good manufacturing practice are excepted from the UDI requirements, and FDA can grant alternatives or exceptions.
The timeline, as it stands.
The rule's dates ran from 2014 to 2018, with later direct-marking dates. FDA's compliance policies for non-sterile class II, class III and implantable or life-supporting devices are no longer in effect.
Three moves that de-risk the deadline.
Confirm each device's status
List every device, its class and whether an exception, alternative or old compliance policy applied. Most grace periods have ended.
Reconcile GUDID with the label
Check that each device identifier in GUDID matches what is printed and encoded on the package.
Plan for the EU too
Devices sold in the EU need an EU UDI and EUDAMED registration as well. One identity design can serve both.
An identity that stays with the device.
A UDI tells a hospital what a device is meant to be. Aeroz adds a physical identity that answers each tap with a signed response and keeps the device's custody and service record, so a counterfeit or a device with a swapped label can be told apart from the genuine one.
FDA UDI for medical devices, answered.
What is an FDA UDI?
A unique device identifier: a code on a medical device's label and package, made of a device identifier and production identifiers, in plain text and machine-readable form.
What is GUDID?
FDA's Global Unique Device Identification Database, where labelers submit key data for each device identifier. The public can search it through AccessGUDID.
Do class I devices need a UDI?
Most do, from 24 September 2018, but class I devices exempt from current good manufacturing practice are excepted.
Are FDA's UDI grace periods still in effect?
Not for most devices. FDA says its compliance policies for non-sterile class III, class II and implantable, life-supporting or life-sustaining devices are no longer in effect.
Know exactly where you stand, in 14 days.
A fixed-fee Aeroz audit maps your products against FDA UDI labelling, GUDID data and direct marking for your devices and returns a written readiness assessment, a data-mapping review, and a scoped pilot plan with cost and timeline.